Merck publishes innovation brochure with interactive features

Merck KGaAMerck KGaA announced today that it has published a new brochure depicting how the company successfully transforms new ideas into innovative products, services and processes. The brochure concisely presents Merck innovations in pharmaceuticals, chemicals and life sciences that help to improve quality of life. Yet the 36-page publication entitled "New. Since 1668." is more than just a print medium. On certain pages, readers using a smartphone can activate animated photos and entertaining pieces of additional information.

"Innovation is a central element of the Merck culture," says Walter Huber, Head of Corporate Communications at Merck. "With the brochure, we'd like to show what makes Merck, its employees and products so innovative as well as what constantly creating innovations and useful new products means to us." The individual examples given in the brochure stand for an entire series of Merck innovations in a wide range of fields. They include injection devices for pharmaceuticals, rapid tests for food, liquid crystals for modern flat screen TVs, services and products for researchers, as well as developments in traditional pharmaceuticals, and biotechnology. Readers also learn why Merck forms research and development partnerships and which achievements date back to Emanuel Merck, the founding father of industrial production at Merck.

Readers who have a smartphone or iPad 2 can, for the first time, use augmented reality technology with a Merck brochure. By starting an app and holding the device camera over a specially marked photo, the static page contents transforms into animated photos. A short video or a bit of 3D animation then explains the page content in a playful manner, offering information beyond what is contained in the text. The "junaio" app runs on smartphones that use the Android operating system as well as on iPhone and iPad 2 and can be downloaded from the Internet free of charge.

Readers without one of these devices can also experience the interactive features of the brochure: a special Web version offers a few surprises.

The brochure is available in German, English, French and Spanish. A new edition of the company profile "The Merck Group. An Overview" has also been published. Together with image brochure "The Merck Way", which was published last year, the publications answer the following questions: "Who is Merck?" "What does Merck do?" "What does Merck achieve?" All three brochures can be ordered together in a single folder.

About Merck KGaA
Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...